Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis
- PMID:10430735
- DOI:10.1164/ajrccm.160.2.9810008
Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis
Abstract
Pulmonary hypertension is a life-threatening complication of lung fibrosis. Vasodilator therapy is difficult owing to systemic side effects and pulmonary ventilation-perfusion mismatch. We compared the effects of intravenous prostacyclin and inhaled NO and aerosolized prostacyclin in randomized order and, in addition, tested for effects of oxygen and systemic calcium antagonists (CAAs) in eight patients with lung fibrosis and pulmonary hypertension. Aerosolized prostaglandin (PG)I(2) caused preferential pulmonary vasodilatation with a decrease in mean pulmonary arterial pressure from 44.1 +/- 4.2 to 31.6 +/- 3.1 mm Hg, and pulmonary vascular resistance (RL) from 810 +/- 226 to 386 +/- 69 dyn. s. cm(-)(5) (p < 0.05, respectively). Systemic arterial pressure, arterial oxygen saturation, and pulmonary right-to-left shunt flow, measured by multiple inert gas analysis, were not significantly changed. Inhaled NO similarly resulted in selective pulmonary vasodilatation, with RL decreasing from 726 +/- 217 to 458 +/- 81 dyn. s. cm(-)(5). In contrast, both intravenous PGI(2) and CAAs were not pulmonary selective, resulting in a significant drop in arterial pressure. In addition, PGI(2) infusion caused a marked increase in shunt flow. Long-term therapy with aerosolized iloprost (long-acting PGI(2) analog) resulted in unequivocal clinical improvement from a state of immobilization and severe resting dyspnea in a patient with decompensated right heart failure. We concluded that, in pulmonary hypertension secondary to lung fibrosis, aerosolization of PGI(2) or iloprost causes marked pulmonary vasodilatation with maintenance of gas exchange and systemic arterial pressure. Long-term therapy with inhaled iloprost may be life saving in decompensated right heart failure from pulmonary hypertension secondary to lung fibrosis.
Similar articles
-
[Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to pulmonary fibrosis].Pneumologie. 2000 Mar;54(3):133-42. doi: 10.1055/s-2000-9076. Pneumologie. 2000. PMID:10783653 Clinical Trial. German.
-
Aerosolized prostacyclin and iloprost in severe pulmonary hypertension.Ann Intern Med. 1996 May 1;124(9):820-4. doi: 10.7326/0003-4819-124-9-199605010-00006. Ann Intern Med. 1996. PMID:8610951
-
Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial.Lancet. 2002 Sep 21;360(9337):895-900. doi: 10.1016/S0140-6736(02)11024-5. Lancet. 2002. PMID:12354470 Clinical Trial.
-
Inhaled iloprost in pulmonary arterial hypertension.Ann Pharmacother. 2005 Jul-Aug;39(7-8):1265-74. doi: 10.1345/aph.1E575. Ann Pharmacother. 2005. PMID:15976392 Review.
-
Inhaled Therapies for Pulmonary Hypertension.Respir Care. 2015 Jun;60(6):794-802; discussion 802-5. doi: 10.4187/respcare.03927. Respir Care. 2015. PMID:26070575 Review.
Cited by
-
Pathogenesis, clinical features, and phenotypes of pulmonary hypertension associated with interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative - Group 3 Pulmonary Hypertension.Pulm Circ. 2023 Apr 1;13(2):e12213. doi: 10.1002/pul2.12213. eCollection 2023 Apr. Pulm Circ. 2023. PMID:37025209 Free PMC article. Review.
-
PAH-specific therapy for pulmonary hypertension and interstitial lung disease: A systemic review and meta-analysis.Front Cardiovasc Med. 2022 Nov 17;9:992879. doi: 10.3389/fcvm.2022.992879. eCollection 2022. Front Cardiovasc Med. 2022. PMID:36465444 Free PMC article.
-
Heart Failure After Right Ventricular Myocardial Infarction.Curr Heart Fail Rep. 2022 Dec;19(6):375-385. doi: 10.1007/s11897-022-00577-8. Epub 2022 Oct 5. Curr Heart Fail Rep. 2022. PMID:36197627 Free PMC article. Review.
-
Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative-Group 3 pulmonary hypertension.Pulm Circ. 2022 Jul 1;12(3):e12127. doi: 10.1002/pul2.12127. eCollection 2022 Jul. Pulm Circ. 2022. PMID:36016668 Free PMC article. Review.
-
Group 3 Pulmonary Hypertension: From Bench to Bedside.Circ Res. 2022 Apr 29;130(9):1404-1422. doi: 10.1161/CIRCRESAHA.121.319970. Epub 2022 Apr 28. 中国保监会研究》2022。 PMID:35482836 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials